2,085 reports of this reaction
2.0% of all EVEROLIMUS reports
#11 most reported adverse reaction
DECREASED APPETITE is the #11 most commonly reported adverse reaction for EVEROLIMUS, manufactured by Novartis Pharmaceuticals Corporation. There are 2,085 FDA adverse event reports linking EVEROLIMUS to DECREASED APPETITE. This represents approximately 2.0% of all 106,093 adverse event reports for this drug.
Patients taking EVEROLIMUS who experience decreased appetite should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DECREASED APPETITE is a less commonly reported adverse event for EVEROLIMUS, but still significant enough to appear in the safety profile.
In addition to decreased appetite, the following adverse reactions have been reported for EVEROLIMUS:
The following drugs have also been linked to decreased appetite in FDA adverse event reports:
DECREASED APPETITE has been reported as an adverse event in 2,085 FDA reports for EVEROLIMUS. This does not prove causation, but indicates an association observed in post-market surveillance data.
DECREASED APPETITE accounts for approximately 2.0% of all adverse event reports for EVEROLIMUS, making it a notable side effect.
If you experience decreased appetite while taking EVEROLIMUS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.